Bimekizumab Significantly Improves Joint, Skin Symptoms in Psoriatic Arthritis
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.